| Cost-effectiveness of empagliflozin for the treatment of patients with type 2 diabetes mellitus at increased cardiovascular risk in Greece G Gourzoulidis, C Tzanetakos, I Ioannidis, A Tsapas, G Kourlaba, ... Clinical Drug Investigation 38, 417-426, 2018 | 41 | 2018 |
| Cost-effectiveness of dapagliflozin as add-on to metformin for the treatment of type 2 diabetes mellitus in Greece C Tzanetakos, N Tentolouris, G Kourlaba, N Maniadakis Clinical drug investigation 36, 649-659, 2016 | 37 | 2016 |
| Cost-effectiveness analysis of liraglutide versus sitagliptin or exenatide in patients with inadequately controlled type 2 diabetes on oral antidiabetic drugs in Greece C Tzanetakos, A Melidonis, C Verras, G Kourlaba, N Maniadakis BMC health services research 14, 1-13, 2014 | 30 | 2014 |
| Cost effectiveness of exenatide once weekly versus insulin glargine and liraglutide for the treatment of type 2 diabetes mellitus in Greece C Tzanetakos, A Bargiota, G Kourlaba, G Gourzoulidis, N Maniadakis Clinical drug investigation 38, 67-77, 2018 | 18 | 2018 |
| PNS61 does a standard willingness-to-pay threshold exist in Greece? C Tzanetakos, G Stefanou, G Gourzoulidis Value in Health 22, S772-S773, 2019 | 11 | 2019 |
| Does a standard cost-effectiveness threshold exist? The case of Greece C Tzanetakos, G Gourzoulidis Value in Health Regional Issues 36, 18-26, 2023 | 10 | 2023 |
| Cost-effectiveness of tofacitinib for the treatment of moderate to severe active ulcerative colitis in Greece K Vellopoulou, G Stefanou, C Tzanetakos, N Boubouchairopoulou, ... European Journal of Gastroenterology & Hepatology 33 (3), 325-333, 2021 | 10 | 2021 |
| Cost-effectiveness of Empagliflozin compared with Dapagliflozin for the treatment of patients with type 2 diabetes mellitus and established cardiovascular disease in Greece G Gourzoulidis, C Tzanetakos, I Ioannidis, V Tsimihodimos, V Diogo, ... Clinical Drug Investigation 41, 371-380, 2021 | 6 | 2021 |
| Cost-utility analysis of certolizumab pegol in combination with methotrexate in patients with moderate-to-severe active rheumatoid arthritis in Greece C Tzanetakos, A Tzioufas, A Goules, G Kourlaba, T Theodoratou, ... Rheumatology International 37, 1441-1452, 2017 | 6 | 2017 |
| Cost-effectiveness analysis of intravitreal aflibercept in the treatment of neovascular age-related macular degeneration In Greece G Kourlaba, C Tzanetakos, J Datseris, A Rouvas, D Arzoumanidou, ... Value in Health 18 (7), A421, 2015 | 6 | 2015 |
| Health and economic outcomes of 20-valent pneumococcal conjugate vaccine compared to 15-valent pneumococcal conjugate vaccine strategies for adults in Greece G Gourzoulidis, M Barmpouni, V Kossyvaki, J Vietri, C Tzanetakos Frontiers in public health 11, 1229524, 2023 | 3 | 2023 |
| Cost-effectiveness analysis of lorlatinib in patients previously treated with anaplastic lymphoma kinase inhibitors for non-small cell lung cancer in Greece G Gourzoulidis, O Zisimopoulou, N Boubouchairopoulou, C Michailidi, ... Journal of health economics and outcomes research 9 (1), 50, 2022 | 3 | 2022 |
| Cost-effectiveness of selexipag for the treatment of pulmonary arterial hypertension (PAH) in Greece A Solakidi, C Tzanetakos, A Beaudet, A Zervoudaki, C Lamprou, ... Value in Health 20 (9), A645, 2017 | 3 | 2017 |
| Budget impact analysis of empagliflozin for the treatment of patients with type 2 diabetes mellitus at increased cardiovascular risk in Greece G Gourzoulidis, C Tzanetakos, I Ioannidis, A Tsapas, G Kourlaba, ... Value in Health 20 (9), A476, 2017 | 3 | 2017 |
| Cost-utility analysis of certolizumab pegol for the treatment of active psoriatic arthritis in Greece C Tzanetakos, D Vassilopoulos, G Kourlaba, P Christou, N Maniadakis Value in Health 18 (7), A646-A647, 2015 | 3 | 2015 |
| PBI28 Cost-effectiveness of certolizumab pegol for the treatment of moderate to severe plaque psoriasis in Greece G Gourzoulidis, D Rigopoulos, V Kountouris, P Christou, S Kiri, ... Value in Health 22, S422, 2019 | 2 | 2019 |
| PCN141-COST-EFFECTIVENESS ANALYSIS OF OBINUTUZUMAB FOR THE TREATMENT OF PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED FOLLICULAR LYMPHOMA IN GREECE K Vellopoulou, C Tzanetakos, T Theodoropoulou, A Akratos, ... Value in Health 21, S38, 2018 | 2 | 2018 |
| EE194 Economic Evaluation of Tofacitinib for the Treatment of Active Polyarticular Juvenile Idiopathic Arthritis in Greece C Tzanetakos, A Solakidi, M Psarra, E Nikitopoulou, G Gourzoulidis Value in Health 26 (12), S88, 2023 | 1 | 2023 |
| EE264 Cost-Effectiveness Analysis of Upadacitinib in Patients with Active Non-Radiographic Axial Spondyloarthritis in Greece C Tzanetakos, I Kotsis, G Gourzoulidis Value in Health 26 (12), S102, 2023 | 1 | 2023 |
| EE106 Cost-effectiveness analysis of bimekizumab in patients with moderate-to-severe plaque psoriasis in Greece M Koulentaki, C Tzanetakos, A Stratigos, E Sotiriou, I Ladha, P Christou, ... Value in Health 25 (12), S74, 2022 | 1 | 2022 |
